Dan Howard

1.1k total citations
24 papers, 891 citations indexed

About

Dan Howard is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Dan Howard has authored 24 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Cardiology and Cardiovascular Medicine and 7 papers in Oncology. Recurrent topics in Dan Howard's work include Diabetes Treatment and Management (9 papers), Blood Pressure and Hypertension Studies (8 papers) and Renin-Angiotensin System Studies (8 papers). Dan Howard is often cited by papers focused on Diabetes Treatment and Management (9 papers), Blood Pressure and Hypertension Studies (8 papers) and Renin-Angiotensin System Studies (8 papers). Dan Howard collaborates with scholars based in United States, Switzerland and France. Dan Howard's co-authors include William P. Dole, H. A. Dieterich, Sujata Vaidyanathan, Marie‐Noëlle Bizot, Ron Sabo, Venkateswar Jarugula, Monica Ligueros‐Saylan, Yibin Wang, Joelle Campestrini and Gangadhar Sunkara and has published in prestigious journals such as PLoS ONE, Clinical Pharmacokinetics and British Journal of Clinical Pharmacology.

In The Last Decade

Dan Howard

23 papers receiving 850 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dan Howard United States	16	523	253	237	230	153	24	891
Marina De Smet United States	17	232 0.4×	188 0.7×	132 0.6×	183 0.8×	289 1.9×	21	1.1k
Eva Ludwig-Schwellinger Germany	8	204 0.4×	479 1.9×	251 1.1×	367 1.6×	170 1.1×	9	1.3k
David J. Kazierad United States	14	192 0.4×	166 0.7×	136 0.6×	72 0.3×	108 0.7×	27	560
Terry Sullivan United States	7	179 0.3×	123 0.5×	129 0.5×	169 0.7×	186 1.2×	8	825
Venkateswar Jarugula United States	15	149 0.3×	273 1.1×	197 0.8×	156 0.7×	61 0.4×	24	655
Arne Ring Germany	21	1.1k 2.1×	149 0.6×	411 1.7×	462 2.0×	491 3.2×	53	1.5k
Bernard E. Ilson United States	17	204 0.4×	360 1.4×	96 0.4×	55 0.2×	112 0.7×	33	825
Stefan Blech Germany	6	163 0.3×	450 1.8×	120 0.5×	99 0.4×	126 0.8×	8	771
Aditi Sapre United States	13	420 0.8×	178 0.7×	90 0.4×	97 0.4×	882 5.8×	23	1.2k
Vibeke Hatorp Denmark	12	510 1.0×	28 0.1×	239 1.0×	182 0.8×	194 1.3×	15	780

Countries citing papers authored by Dan Howard

Since Specialization

Citations

This map shows the geographic impact of Dan Howard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Howard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Howard more than expected).

Fields of papers citing papers by Dan Howard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Howard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Howard. The network helps show where Dan Howard may publish in the future.

Co-authorship network of co-authors of Dan Howard

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Howard. A scholar is included among the top collaborators of Dan Howard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Howard. Dan Howard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seifert, Marva, Nicole A. Stadnick, Carrie M. Geremia, et al.. (2025). Diabetic Retinopathy Screening Among Federally Qualified Health Center Patients Using Point-of-Care AI. JAMA Network Open. 8(10). e2538114–e2538114.

Jarugula, Venkateswar, Ching‐Ming Yeh, Dan Howard, et al.. (2010). Influence of Body Weight and Gender on the Pharmacokinetics, Pharmacodynamics, and Antihypertensive Efficacy of Aliskiren. The Journal of Clinical Pharmacology. 50(12). 1358–1366. 14 indexed citations

Hu, Pei, Michael G. Bartlett, Ji Jiang, et al.. (2010). Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese Subjects. Clinical Drug Investigation. 30(4). 221–228. 3 indexed citations

Vaidyanathan, Sujata, Gian Camenisch, Christine Reynolds, et al.. (2008). Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren. The Journal of Clinical Pharmacology. 48(11). 1323–1338. 87 indexed citations

Ayalasomayajula, Surya, Ching‐Ming Yeh, Sujata Vaidyanathan, et al.. (2008). Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects. The Journal of Clinical Pharmacology. 48(7). 799–811. 14 indexed citations

He, Handan, Hequn Yin, Harold T. Smith, et al.. (2008). Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans. Drug Metabolism and Disposition. 37(3). 536–544. 119 indexed citations

He, Handan, Hequn Yin, Harold T. Smith, et al.. (2008). Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs. Drug Metabolism and Disposition. 37(3). 545–554. 25 indexed citations

Vaidyanathan, Sujata, Michael G. Bartlett, H. A. Dieterich, et al.. (2008). Pharmacokinetic Interaction of the Direct Renin Inhibitor Aliskiren with Furosemide and Extended‐Release Isosorbide‐5‐Mononitrate in Healthy Subjects. Cardiovascular Therapeutics. 26(4). 238–246. 9 indexed citations

Vaidyanathan, Sujata, Venkateswar Jarugula, H. A. Dieterich, Dan Howard, & William P. Dole. (2008). Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren. Clinical Pharmacokinetics. 47(8). 515–531. 123 indexed citations

10.

Vaidyanathan, Sujata, Mojdeh Maboudian, Ching‐Ming Yeh, et al.. (2008). A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Current Medical Research and Opinion. 24(8). 2313–2326. 17 indexed citations

11.

He, Yanling, Ron Sabo, Joelle Campestrini, et al.. (2007). The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. British Journal of Clinical Pharmacology. 65(3). 338–346. 56 indexed citations

12.

Sunkara, Gangadhar, Ron Sabo, Yibin Wang, et al.. (2007). Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers. The Journal of Clinical Pharmacology. 47(9). 1152–1158. 38 indexed citations

13.

He, Yanling, Ron Sabo, Gangadhar Sunkara, et al.. (2007). Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers. The Journal of Clinical Pharmacology. 47(8). 998–1004. 33 indexed citations

14.

He, Yanling, Brian M. Sadler, Ron Sabo, et al.. (2007). The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers. Clinical Pharmacokinetics. 46(9). 787–802. 64 indexed citations

15.

Morrison, Dennis, Sandip Kumar Roy, Craig R. Rayner, et al.. (2007). A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination. PLoS ONE. 2(12). e1305–e1305. 49 indexed citations

16.

Vaidyanathan, Sujata, Christine Reynolds, Ching‐Ming Yeh, et al.. (2007). Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects. The Journal of Clinical Pharmacology. 47(4). 453–460. 43 indexed citations

17.

He, Yanling, Ron Sabo, Gilles‐Jacques Rivière, et al.. (2007). Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Current Medical Research and Opinion. 23(5). 1131–1138. 33 indexed citations

18.

He, Yanling, Monica Ligueros‐Saylan, Gangadhar Sunkara, et al.. (2007). Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects. The Journal of Clinical Pharmacology. 48(1). 85–95. 38 indexed citations

19.

Vaidyanathan, Sujata, Hilde Bigler, Marie‐Noëlle Bizot, et al.. (2007). Pharmacokinetics of the Oral Direct??Renin Inhibitor Aliskiren Alone and??in Combination with Irbesartan in??Renal Impairment. Clinical Pharmacokinetics. 46(8). 661–675. 56 indexed citations

20.

Shi, Jun Yi, Marc Pfister, Stephen G. Jenkins, et al.. (2005). Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia. Clinical Pharmacokinetics. 44(3). 317–329. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact